James J Hsieh
Overview
Explore the profile of James J Hsieh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
9089
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee C, Shah A, Rao A, Taylor M, Di Simone C, Hsieh J, et al.
Eur Urol
. 2024 May;
86(5):470-473.
PMID: 38777648
No abstract available.
2.
Ricketts C, de Cubas A, Fan H, Smith C, Lang M, Reznik E, et al.
Cell Rep
. 2024 Apr;
43(4):113063.
PMID: 38578829
No abstract available.
3.
Wu Y, Terekhanova N, Caravan W, Naser Al Deen N, Lal P, Chen S, et al.
Nat Commun
. 2023 May;
14(1):2817.
PMID: 37198186
No abstract available.
4.
Wu Y, Terekhanova N, Caravan W, Naser Al Deen N, Lal P, Chen S, et al.
Nat Commun
. 2023 Mar;
14(1):1681.
PMID: 36973268
Identifying tumor-cell-specific markers and elucidating their epigenetic regulation and spatial heterogeneity provides mechanistic insights into cancer etiology. Here, we perform snRNA-seq and snATAC-seq in 34 and 28 human clear cell...
5.
Xie Y, Sahin M, Wakamatsu T, Inoue-Yamauchi A, Zhao W, Han S, et al.
JCI Insight
. 2023 Feb;
8(4).
PMID: 36810256
SETD2, a H3K36 trimethyltransferase, is the most frequently mutated epigenetic modifier in lung adenocarcinoma, with a mutation frequency of approximately 9%. However, how SETD2 loss of function promotes tumorigenesis remains...
6.
Nixon B, Kuo F, Ji L, Liu M, Capistrano K, Do M, et al.
Immunity
. 2022 Oct;
55(11):2044-2058.e5.
PMID: 36288724
Tumors are populated by antigen-presenting cells (APCs) including macrophage subsets with distinct origins and functions. Here, we examined how cancer impacts mononuclear phagocytic APCs in a murine model of breast...
7.
Miheecheva N, Postovalova E, Lyu Y, Ramachandran A, Bagaev A, Svekolkin V, et al.
Cell Rep
. 2022 Aug;
40(7):111180.
PMID: 35977503
Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed...
8.
Zaitsev A, Chelushkin M, Dyikanov D, Cheremushkin I, Shpak B, Nomie K, et al.
Cancer Cell
. 2022 Aug;
40(8):879-894.e16.
PMID: 35944503
Cellular deconvolution algorithms virtually reconstruct tissue composition by analyzing the gene expression of complex tissues. We present the decision tree machine learning algorithm, Kassandra, trained on a broad collection of...
9.
Lee C, Motzer R, Emamekhoo H, Matrana M, Percent I, Hsieh J, et al.
Clin Cancer Res
. 2022 May;
28(15):3248-3255.
PMID: 35576438
Purpose: Glutaminase is a key enzyme, which supports elevated dependency of tumors on glutamine-dependent biosynthesis of metabolic intermediates. Dual targeting of glucose and glutamine metabolism by the mTOR inhibitor everolimus...
10.
Lee C, Gundem G, Lee W, Chen Y, Cross J, Dong Y, et al.
JCO Precis Oncol
. 2022 Feb;
1.
PMID: 35172488
Patients And Methods: Three patients with lethal kidney cancer (age 19, 20, and 37 years) exhibiting persistent (1 to 3 months) extremely high levels of blood lactate (> 5 mM)...